Altesa BioSciences, Inc. — SEC Form D Filing

Altesa BioSciences, Inc. filed an SEC Form D on February 23, 2026, reporting $75.00M raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
February 23, 2026
Amount reported
$75.00M
Round stage
Seed
Industry
Pharmaceuticals
Website
https://www.altesabio.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Altesa BioSciences addresses the challenge of developing safer and more effective therapeutic agents.

Solution

The company focuses on leveraging its proprietary technology to create innovative drug delivery systems.

Why now

There is a growing need for advanced therapeutic methods to improve patient outcomes in healthcare.

Verdict

Investors said yes at this moment largely due to the compelling narrative around advanced therapeutic methods and a clear focus on innovative drug delivery systems, which cleared because of the perceived urgency in healthcare needs, not simply because of a well-defined technology. They were implicitly betting on scaling proprietary technology to create safer drug delivery solutions, assuming those benefits would translate into substantial market demand. However, the limited upside stemmed from the intense competition in personalized medicine, which could quickly commoditize their innovations.

Source: SEC EDGAR Form D filing